| Name | Title | Contact Details |
|---|
Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Progyny is a transformative fertility, family building, and women`s health benefits solution, trusted by the nation`s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women`s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare`s Best Places to Work in Healthcare, Forbes` Best Employers, Financial Times, INC. 5000, Inc Power Partners and Crain`s Fast 50 for NYC.
Changing lives with next generation peptide therapeutics
Highline Sciences is a specialized, full-service CRO and consultancy founded from within an oncology biotech to provide a better solution. We understand the gap between what you need and what you get from a traditional CRO and we’re here to improve the...
As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.